clinical trial · NCT07135453
Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines
University of Alabama at Birmingham·phase4·not yet recruiting·n = 70
VaccinePneumococcal DiseasePneumococcal Vaccine
brief summary
The goal of this study is to learn whether different types of vaccines to prevent bacterial infections are able to effectively create antibodies that defend against certain types of bacteria. We will give two different types of vaccine and evaluate the effectiveness of antibodies produced by each vaccine in killing bacteria.
started
Mar 1, 2026
primary completion
Mar 1, 2027
completion
Aug 1, 2027
last updated
Mar 13, 2026
official title
Novel Serotype Alert: Investigate New Pneumococcal Conjugate Vaccines for Inducing Cross-protection Against Newly Discovered Serotype 33E and Putative Novel Serogroup 33 Serotypes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol